Thebiostartups Domain Overview🔒 SSL Verified

Live Data Status: Analyzed on September 2, 2026|E-commerce & Retail

Welcome to the detailed analysis for thebiostartups.com. This domain is officially recognized as The BioStartups - Accelerating Life Sciences Innovation. According to their official web presence, their primary focus is: "Join The BioStartups community and discover the latest advancements in biotechnology, healthcare, and beyond. Collaborate with like-minded entrepreneurs, investors, and mentors to drive your startup forward.".

↓ Success Stories
↓ Startups Spotlight
↓ Read BioStartups newsletter
↓ Ecosystem partners
↓ Bio-informatics
↓ BioStartups for you
↓ Top Alternatives to thebiostartups.com

Tech Stack: Custom Built / Unknown
Link Profile: Internal Pages: 223Outbound Links: 19
Localization: en

6-Month Traffic Trend Estimate

Estimated Market Value

$911

Based on domain age, authority, and keyword relevance.

TLD Availability Risk

thebiostartups.comAvailable
thebiostartups.netAvailable
thebiostartups.orgTaken
thebiostartups.ioTaken
thebiostartups.coTaken
thebiostartups.aiTaken

Official Contact & Profiles

Emails: [email protected]

Socials:linkedin.com twitter.com linkedin.com

Screenshot or Official Image for thebiostartups.com - The BioStartups - Accelerating Life Sciences Innovation

Visual representation extracted from thebiostartups.com

Content Snippets from thebiostartups.com

"xStep, a Bengaluru-based neurotechnology startup that featured on Shark Tank India, has raised funding from Titan Capital to expand its non-invasive neurorehabilitation platform for people living with neurological disorders such as cerebral palsy, stroke, spinal cord injury and multiple sclerosis. The investment marks xStep's entry into the Titan Capital portfolio. The investment amount remains undisclosed. With the expansion of xStep, its non-invasive spinal neuromodulation platform, the company is helping India take an important step toward becoming a global hub for advanced neurorehabilitation. Neurological disorders are among the leading causes of long-term disability worldwide, yet access to advanced rehabilitation remains limited, especially in emerging markets. xStep is set on changing that by making its technology more affordable and easier to reach for patients and healthcare providers. Developed by SpineX Inc. (US) and manufactured by VIVATRONIX Tech (India), xStep combines non-invasive spinal neuromodulation with structured rehabilitation.  The funding will support commercial expansion across India, manufacturing scale-up, clinical evidence generation and regulatory work in both domestic and international markets. As part of its next phase, xStep has launched xStep One, an integrated neurorehabilitation experience centre in Bengaluru. Through a collaboration with Trexo Robotics, it has also brought the company's wearable robotic gait trainer for children to India, making xStep One one of the first centres in the country to offer both xStep spinal neuromodulation and Trexo robotic gait training within a single integrated rehabilitation programme.  Over the next 12-24 months, xStep plans to build up its manufacturing, expand clinical collaborations in India and abroad, add to the evidence across neurological disorders, and keep developing technologies that connect neuroscience research with day-to-day patient care. It also plans to work more closely with clinicians, hospitals and rehabilitation centres so that this kind of care reaches more patients."

"The Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, government of India, has announced the second date for inviting applications under the Research and Innovation Promotion in Pharma and MedTech (PRIP) Scheme. With a financial outlay of Rs 5,000 crore, the scheme aims to strengthen the country's pharma and MedTech R&D ecosystem by supporting startups, MSMEs, and large companies to move faster in the innovation value chain. Applications are invited for two categories: Preparatory Phase: Projects of startups and MSMEs with the objective of scaling up products or technologies at TRL (Technology Readiness Level) 1, 2 or 3 in priority areas to a higher TRL not exceeding TRL 5 will be eligible. A two-stage process will be followed for these projects, starting with a brief concept note. This will be followed by a detailed application for the selected applicants. The concept notes can be submitted by eligible MSMEs and startups directly or by ecosystem enablers on behalf of promising projects that exist in their network. Financial assistance up to Rs 5 crore per project will be provided under this scheme. Subsequent Phases: Projects in industry, startups, and MSMEs that aspire to scale up the products or technologies present on TRL 4, 5, or 6 in priority sectors to a higher level are eligible. Projects in further stages can apply directly through a detailed application form. Under the scheme, a maximum financial assistance of Rs. 100 crore per project will be provided, subject to a maximum of 35% of the total project cost sanctioned, and the balance amount will have to be co-financed by the applicant."

Key Topics & Focus Areas for thebiostartups.com:

Success Stories

Startups Spotlight

Read BioStartups newsletter

Ecosystem partners

Bio-informatics

BioStartups for you

By comparing thebiostartups.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to thebiostartups.com.

Frequently Asked Questions

Is thebiostartups.com a safe and secure website?

Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.

What is the authority score of thebiostartups.com?

As of September 2, 2026, thebiostartups.com holds an estimated domain authority score of 47/100 based on our VisitRank tracking algorithms.

What are the top alternatives to thebiostartups.com?

You can find the best alternatives and similar sites to thebiostartups.com in our explore section, which includes competitors in the E-commerce & Retail sector.

Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.

Common Misspellings & Typo Domains for thebiostartups.com:

tehbiostartups.comthbiostartups.comthhebiostartups.comthabiostartups.comtheboostartups.comthebiostartups.comthebiostertups.comthebiostartops.comtgebiostartups.comtyebiostartups.com

Top Alternatives to thebiostartups.com

app.foodqs.cn irivnyanyn.com app.bluepage.au jmriascos.space app.therealreal.com savethekoala.com editions ellipses.fr bolatimes.com securefield.ca yellowleafhammocks.com bookof ra deluxe.de Home

"Three South Indian medtech startups have emerged as winners of HealthSprint 2026, a joint initiative of the Consulate General of Israel in Bengaluru and Bengaluru-based Techstartup Accelerator GINSERV, aimed at helping Indian healthcare innovators strengthen their businesses, investability and expand into global markets. The winners were announced after the shortlisted startups pitched their solutions to a panel of cohort guides, mentors and investors from India and Israel. The three winners are: BioCipher Labs, Bengaluru - an AI-powered molecular diagnostics startup. Prodancy, Bengaluru – a medtech company that has developed an indigenous surgical helmet for joint replacement procedures, aimed at replacing imported consumables. Mykare.ai, Kochi – an AI-native patient management platform designed for clinics and smaller hospitals. The winners will receive a fully funded, one-week immersive programme in Israel, giving them an opportunity to engage with the country’s healthcare and innovation ecosystem and explore pathways to validate, scale and expand their businesses into global markets. Speaking about the India-Israel collaboration, Max Shmagin, Deputy Consul General, Consulate General of Israel for South India in Bengaluru, said, “When Indians and Israelis cooperate in sectors such as healthcare, the value goes up. Israel has built a strong health-tech ecosystem, and bringing these capabilities together creates an opportunity to validate and scale solutions between our two countries.”"

"Qure.ai, a global AI technology company focused on healthcare, today announced the appointment of Mihir Bhanushali as Executive Vice President, Global Health, as the company deepens its investment in AI-powered healthcare across low- and middle-income countries (LMICs). Bhanushali joins Qure.ai from Freshworks, where he was Senior Director, Global Sales. A seasoned commercial leader, he has built and scaled high-growth businesses across global markets, with earlier leadership roles at Rippling and Whatfix spanning sales, go-to-market strategy and commercial transformation. At Qure.ai, Bhanushali will lead the next phase of the company's growth across LMICs, with a focus on Africa, Southeast Asia, South Asia and Latin America. His mandate spans the company's solutions for infectious diseases, including tuberculosis and HIV, and care delivery across frontline health systems. Qure.ai has built a strong public health footprint over the past decade, with its AI solutions deployed across 107+ countries and 5,200+ sites. Its work in countries such as Nigeria and Kenya demonstrates how AI can substantially strengthen public health programs — from TB screening and early diagnosis to care delivery. The company is helping nationwide public health systems build digital and AI-native infrastructure that enables healthcare workers and primary care providers to make better decisions and improve patient outcomes. Building on this foundation, Qure.ai is expanding beyond screening and early diagnosis into broader care delivery. At the centre of this expansion is Aira, Qure.ai's AI doctor and clinical co-pilot for frontline healthcare, which brings clinical intelligence, digital workflows and care coordination closer to the point of care, with applications across primary care, telemedicine, HIV, infectious diseases and pandemic preparedness. “Improving healthcare access in low- and middle-income countries has been our ambition from day one, and we see a significant opportunity to scale our work in this space,” said Prashant Warier, Co-founder and CEO, Qure.ai. “AI can radically change healthcare workflows in these markets, and we are expanding our team to scale faster. Mihir brings strong commercial and international experience, and his mandate is to build on what we have already established and take this work to its next stage of growth, including scaling Aira across new markets and use cases.” “Qure.ai has built something meaningful: AI technology that is already being used at scale to address real healthcare challenges across diverse markets,” said Mihir Bhanushali, Executive Vice President, Global Health, Qure.ai. “What makes the opportunity particularly exciting is the potential to take this foundation much further, bringing clinical intelligence to more frontline workers, strengthening health systems and reaching more patients. With solutions such as Aira, Qure.ai is well positioned to shape the next phase of AI-enabled healthcare in these markets.” Qure.ai's work in LMICs is supported by partnerships with governments, healthcare organisations and global health funders, including the Gates Foundation."